Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Mittelman

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic SyndromesGuillermo Garcia-Manero, Valeria Santini, Antonio Almeida, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Blood Advances|August 26, 2020
Guideline-based indicators for adult patients with myelodysplastic syndromesKristina Stojkov, Tobias Silzle, Georg Stussi, et al.
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic SyndromesGuillermo Garcia-Manero, Valeria Santini, Antonio Almeida, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Blood Advances|August 26, 2020
Guideline-based indicators for adult patients with myelodysplastic syndromesKristina Stojkov, Tobias Silzle, Georg Stussi, et al.
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
Pageof 12